Items tagged with Access
Statement by MSF on the official release of the full text of the Trans-Pacific Partnership trade agreement (post)
5 November 2015 - The Trans-Pacific Partnership (TPP) is a trade agreement negotiated between the U.S. and eleven other Pacific Rim nations: Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam. After more than five years of negotiations conducted in secret without the opportunity for public review, the agreed text, which will now be submitted to national processes for final signature and ratification, has been officially and publicly released. Doctors Without Borders/Médecins Sans Frontières (MSF) remains extremely concerned about the inclusion of dangerous provisions that would dismantle public health safeguards enshrined in international law and restrict access to price-lowering generic medicines for millions of people.
LDC pharma IP waiver until 2033 approved by WTO TRIPS Council (post)
November 6, 2015 - After two weeks of high level negotiations between the United States and the Group of Least-Developed Countries, the World Trade Organization committee on intellectual property rights today agreed to extend a waiver allowing LDCs to avoid applying and enforcing IP rights on pharmaceutical products until 2033.
Panel looks at patentability criteria in public health (post)
A recent workshop on patentability criteria illustrated how countries are using the policy space provided by international trade rules to calibrate their patent law. In particular, incremental innovation remains a trying issue for national legislators, speakers said.
WHO Director questions IP rights, drug prices, industry influence (post)
Saying she could speak more freely outside of the World Health Organization, WHO Director General Margaret Chan today told a gathering of think tank representatives at the Graduate Institute of Geneva that intellectual property rights may be unfairly driving up drug prices and that industry lobbying may be interfering with governments’ efforts to take action on behalf of their citizens’ public health.
Global Health Impact Index can help assess effectiveness of key drugs (post)
PLOS ONE: The Global Health Impact Index: Promoting Global Health
50+ US Congress members urge reasonable licensing terms for government-funded medical patents (post)
January 11, 2016 - More than 50 members of the United States Congress today sent a letter urging the US Department of Health and Human Services (HHS) and National Institutes of Health (NIH) to exercise their legal authority to require medical patents that have emerged from government-funded medical research projects to be licensed on reasonable and affordable terms for public use.
To be or not to be exclusive: the sutezolid story (post)
I arrived at the Johns Hopkins University campus with a sense of déjà vu; it was my first visit to my alma mater in years. I had travelled to Baltimore for a meeting about the licensing of sutezolid, a much-awaited drug candidate for treatment of Mycobacterium tuberculosis. The research faculty, technology transfer officers, university administration, and advocates at the meeting felt the weight of the responsibility. We knew that licensing a tuberculosis drug candidate could be a historic event.
Xpert MTB/RIF for tuberculosis testing: access and price in highly privatised health markets (post)
Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) is the biggest recent advance in tuberculosis diagnosis, and since 2010 more than 15 million cartridges have been procured through concessional pricing ($9·98 per cartridge in 2015).1 However, even in countries with a high tuberculosis burden, the private sector is not eligible for concessional pricing for Xpert, nor for other WHO-endorsed tests such as line probe assays (LPA) and liquid cultures. Manufacturers set higher prices for reagents and instruments for private laboratories and institutions than for the public sector, and there are additional costs (such as import duties), and margins imposed by distributors, intermediaries, and laboratories.
WHO Board debate: High prices sow seeds of fake medicines in developing countries (post)
Fake and poor quality medicines are still a growing public health concern particularly in developing countries, according to some World Health Organization members, who said at last week’s WHO Board meeting that the problem comes from the unaffordability of medicines and the lack of a strong surveillance system.
UN High Level Panel On Access To Medicines – first reactions, process explained (post)
A high level panel of experts charged by United Nations secretary general to explore solutions to increase innovation and access to medicines in developing countries gave a briefing on February 1st to explain the process of the initiative. Intellectual property is often seen as both a barrier to the diffusion of health technologies and an innovation enabler.
Page 17 of 83 · Total posts: 0
←First 16 17 18 Last→